GFAP and COVID-19: Two plasma biomarkers of CNS injury, neurofilament light-chain protein (NfL, a marker of neuroaxonal injury) and glial fibrillary acidic protein (GFAP, a marker of astrocytic activation/injury), were increased in severe COVID-19 patients [77].